Corcept Therapeutics News

On April 10, 2012, Corcept began offering its first medicine, Korlym , less than eight weeks after the United States Food and Drug Administration approved it as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are ... (more)

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports.

Corcept Therapeutics Incorporated - Financial and Strategic SWOT Analysis Review Summary Corcept Therapeutics Incorporated is a research focused pharmaceutical company discovering, developing and commercializing innovative therapeutics in the areas of psychiatric and metabolic diseases.

Endogenous Cushing's syndrome is a rare and life-threatening endocrine disorder.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia MENLO PARK, CA-- - Corcept Therapeutics Incorporated announced today that Korlym 300 mg Tablets is available by prescription nationwide.